Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ

Watchlist Manager
Eckert & Ziegler Strahlen und Medizintechnik AG Logo
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Watchlist
Price: 55.55 EUR -1.16% Market Closed
Market Cap: 1.2B EUR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+16%
Revenue
Forecast
+22%
Operating Income
Forecast
N/A
Net Income
Forecast
+119%

Wall Street
Price Targets

EUZ Price Targets Summary
Eckert & Ziegler Strahlen und Medizintechnik AG

Wall Street analysts forecast EUZ stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EUZ is 64.41 EUR with a low forecast of 60.9 EUR and a high forecast of 69.3 EUR.

EUZ Lowest Forecast
Wall Street Target
60.9 EUR
10% Upside
EUZ Average Forecast
Wall Street Target
64.41 EUR
16% Upside
EUZ Highest Forecast
Wall Street Target
69.3 EUR
25% Upside
Lowest
Price Target
60.9 EUR
10% Upside
Average
Price Target
64.41 EUR
16% Upside
Highest
Price Target
69.3 EUR
25% Upside
Eckert & Ziegler Strahlen und Medizintechnik AG Competitors:
Price Targets
B
301367
BMC Medical Co Ltd
2% Downside
S
STXS
Stereotaxis Inc
164% Upside
W
336570
Won Tech Co Ltd
8% Upside
ZBH
Zimmer Biomet Holdings Inc
9% Upside
B
301367
BMC Medical Co Ltd
2% Downside
S
STXS
Stereotaxis Inc
164% Upside
W
336570
Won Tech Co Ltd
8% Upside
ZBH
Zimmer Biomet Holdings Inc
9% Upside
P
PRCT
Procept Biorobotics Corp
61% Upside
688236
Beijing Chunlizhengda Medical Instruments Co Ltd
51% Upside
C
214150
Classys Inc
25% Upside
ALKLH
Klea Holding
144% Upside

Revenue
Forecast

Revenue Estimate
Eckert & Ziegler Strahlen und Medizintechnik AG

For the last 8 years the compound annual growth rate for Eckert & Ziegler Strahlen und Medizintechnik AG's revenue is 7%. The projected CAGR for the next 3 years is 13%.

7%
Past Growth
13%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Eckert & Ziegler Strahlen und Medizintechnik AG

For the last 8 years the compound annual growth rate for Eckert & Ziegler Strahlen und Medizintechnik AG's operating income is 29%. The projected CAGR for the next 3 years is 21%.

29%
Past Growth
21%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Eckert & Ziegler Strahlen und Medizintechnik AG

For the last 8 years the compound annual growth rate for Eckert & Ziegler Strahlen und Medizintechnik AG's net income is 12%. The projected CAGR for the next 3 years is 28%.

12%
Past Growth
28%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

See Also

Summary
EUZ intrinsic value, competitors valuation, and company profile.
DCF Valuation
EUZ stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EUZ stock valuation using valuation multiples.
Wall Street Estimates
EUZ price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EUZ stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EUZ's stock price target?
Price Target
64.41 EUR

According to Wall Street analysts, the average 1-year price target for EUZ is 64.41 EUR with a low forecast of 60.9 EUR and a high forecast of 69.3 EUR.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Revenue forecast?
Projected CAGR
13%

For the last 8 years the compound annual growth rate for Eckert & Ziegler Strahlen und Medizintechnik AG's revenue is 7%. The projected CAGR for the next 3 years is 13%.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Operating Income forecast?
Projected CAGR
21%

For the last 8 years the compound annual growth rate for Eckert & Ziegler Strahlen und Medizintechnik AG's operating income is 29%. The projected CAGR for the next 3 years is 21%.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Net Income forecast?
Projected CAGR
28%

For the last 8 years the compound annual growth rate for Eckert & Ziegler Strahlen und Medizintechnik AG's net income is 12%. The projected CAGR for the next 3 years is 28%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.